Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Wellnex Life Ltd ( (AU:WNX) ).
Wellnex Life Limited has reached an agreement with 365 Health to defer the next payment for the Pain Away acquisition, aligning it with its planned dual listing on the London Stock Exchange (LSE) in March 2025. This strategic move aims to provide Wellnex Life access to a broader investor base and stronger capital support, enhancing its market position and growth potential both domestically and globally. The acquisition of Pain Away has significantly boosted the company’s revenue, with record sales reported in late 2024, and continues to drive growth across its brands and IP licensing ventures.
More about Wellnex Life Ltd
Wellnex Life Limited is a consumer healthcare business known for developing, licensing, and marketing health-related products and brands. Since its inception in 2021, the company has established significant distribution channels in major Australian retailers and globally, partnering with major pharmaceutical firms. Its product lineup has been enhanced by the acquisition of Pain Away, a leading topical pain relief brand, accelerating its growth in the healthcare market.
YTD Price Performance: -2.00%
Average Trading Volume: 7,500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €12.33M
See more insights into WNX stock on TipRanks’ Stock Analysis page.
